The proteasome inhibitor bortezomib has demonstrated high antitumor
activity in multiple myeloma (MM). Peripheral neuropathy (PNP) is a doselimiting toxicity of bortezomib, which typically occurs within the first cycles of bortezomib in 30-40% of MM patients. Although bortezomib induced PNP is manageable and reversible in most MM patients, no effective prophylactic treatment against PNP is available and bortezomib discontinuation is frequently required. Identifying patients at risk of neuropathy and understanding its pathogenesis is therefore of great importance.
Click on PDF tab to view and download the document